Psilocybin Efficacy and Mechanisms of Action in Major Depressive Disorder: a Review
Psilocybin Efficacy and Mechanisms of Action in Major Depressive Disorder: a Review
复制标题
裸盖菇素治疗重度抑郁症的功效和作用机制：综述
作者：
Damien Prouzeau;Ismael Conejero;Peter L. Voyvodic;C. Bécamel;M. Abbar;J. López
审查的目的，我们的目的是提供一个概述的知识状态的裸盖菇素在治疗抑郁症的疗效，以及其作用机制。最近的发现裸盖菇素在治疗顽固性或临终抑郁症方面具有巨大，快速和持久的临床效果。耐受性良好，轻度副作用仅限于给药后几小时。迄今为止进行的研究样本量较小。一项针对参比治疗（艾司西酞普兰）的临床试验未显示裸盖菇素在主要结局方面的显著优效性。神经生物学机制，大多未知，不同于SSRI抗抑郁药。摘要裸盖菇素是治疗抑郁症的一种有前途的替代方案。需要进一步研究更大的样本量，特别是对参考治疗，以更好地了解其影响的神经生物学因素，并调查其在日常实践中使用的潜力。
Purpose of the Review We aim to provide an overview of the current state of knowledge about the efficacy of psilocybin in the treatment of depression, as well as its mechanisms of action. Recent Findings Psilocybin has a large, rapid, and persistent clinical effect in the treatment of resistant or end-of-life depression. Tolerance is good, with mild side effects limited to a few hours after dosing. The studies conducted to date have had small sample sizes. One clinical trial has been conducted against a reference treatment (escitalopram) without showing a significant superiority of psilocybin in the main outcome. The neurobiological mechanisms, mostly unknown, differ from those of SSRI antidepressants. Summary Psilocybin represents a promising alternative in the treatment of depression. Further research with larger sample sizes, particularly against reference treatments, is needed to better understand the neurobiological factors of its effects and to investigate its potential for use in everyday practice.
影响因子：
4.6
作者：
Treadway, Michael T.;Bossaller, Nicholas A.;Shelton, Richard C.;Zald, David H.
通讯作者：
Zald, David H.